Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease

Movement Disorders

Volumn 21, Issue 1, 2006, Pages 94-98

  Schweitzer, Katherine J ^a   Hilker, Rüdiger ^b   Walter, Uwe ^c   Berg, Daniela ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Disease progression; Parkinson's disease; Predisposition; SN hyperechogenicity; Transcranial sonography (TCS)

Indexed keywords

6 FLUORODOPA F 18;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; ECHOENCEPHALOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; SYMPTOM;

EID: 33244497832     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20669     Document Type: Article

References (23)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
2. Koller WC. When does Parkinson's disease begin? Neurology 1992;42:27-31.
3. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36: 759-764.
4. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
5. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
6. Hilker R, Schweitzer K, Coburger S, et al. Progression of Parkinson's disease is non-linear as determined by serial PET imaging of striatal [18]fluorodopa activity. Arch Neurol 2005;62:378-382.
7. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992;7:110-116.
8. Gasser T. Overview of the genetics of Parkinsonism. Adv Neurol 2003;91:143-152.
9. Golbe LI, Mouradian MM. Alpha-synuclein in Parkinson's disease: light from two new angles. Ann Neurol 2004;55:153-156.
10. Shastry BS. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 2001;41:5-12.
11. von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004;73:151-177.
12. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
13. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.
14. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002;109: 191-196.
15. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53: 1026-1031.
16. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
17. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
18. Luecking CB, Deurr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene: French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
19. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004;19:1445-1449.
20. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
21. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247(Suppl. 2):II11-II18.
22. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by trasncranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001;50:463-467.
23. Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17.